Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
HNRNPU Lactylation and Cervical Cancer Metabolism
2026-11-17
A 2026 study proposed that HNRNPU K181 lactylation connects lactate accumulation to PHGDH transcript regulation, serine metabolism, and cervical cancer growth. Its genetic and multi-model evidence supports a mechanistic axis, while the pleiotropic pharmacology and limited model scope constrain claims about therapeutic translation and the separate role of (R)-MG132.
HNRNPU Lactylation and Cervical Cancer Metabolism
2026-11-17
A literature-focused analysis of how HNRNPU K181 lactylation was linked to PHGDH regulation, serine metabolic rewiring, and cervical cancer growth, while separating genetic evidence from pharmacological confounding and the distinct control role of (R)-MG132.
HNRNPU Lactylation in Cervical Cancer Metabolism
2026-11-16
A literature-focused analysis of how HNRNPU K181 lactylation may connect lactate accumulation with PHGDH regulation, serine metabolism, and cervical cancer growth, while separating the study’s pharmacological evidence from the distinct proteasome-control role of (R)-MG132.
When Context Changes a Molecular Result
2026-11-16
A cervical-cancer study links HNRNPU K181 lactylation to PHGDH expression, serine metabolism and tumor growth, but each result supports a different level of inference. The contrasting role of (R)-MG132 as a stereoisomeric proteasome control shows why material identity, comparator choice, model and readout must remain connected.
What (R)-MG132 Can—and Cannot—Show
2026-11-15
The cervical-cancer study supports a lactate-responsive HNRNPU K181–PHGDH axis that connects post-translational regulation with serine metabolism and tumor growth. (R)-MG132 has a different evidentiary role: as a low-activity stereoisomeric proteasome control, it can help separate proteasome-dependent effects from the lactylation mechanism, but it cannot establish that mechanism itself.
CCR7–Notch1 Crosstalk in Mammary Cancer Stemness
2026-11-14
Boyle et al. used genetic, pharmacological, molecular and functional readouts in an MMTV-PyMT mouse model to investigate how CCR7 signaling intersects with Notch1 in mammary cancer stem-like cells. The findings support a context-dependent signaling relationship, while leaving clinical causality, therapeutic efficacy and broader applicability unresolved.
When Context Changes a Biological Result
2026-11-13
A cervical-cancer study illustrates how model, perturbation, comparator, and readout determine what a molecular result can mean. The associated (R)-MG132 material has a distinct control role in proteasome research and should not be treated as evidence for the reported lactylation mechanism.
HNRNPU Lactylation and the Role of (R)-MG132
2026-11-13
A 2026 study links HNRNPU K181 lactylation to PHGDH transcript regulation, serine metabolism, and cervical cancer growth. Its findings also clarify why (R)-MG132 should be interpreted as a low-activity proteasome-control compound rather than as the causal perturbation underlying this pathway.
HNRNPU Lactylation and (R)-MG132
2026-11-12
The cervical-cancer study supports a lactate–HNRNPU–PHGDH axis, but it does not establish (R)-MG132 as a causal probe of that mechanism. This editorial distinguishes the study’s evidence for post-translational regulation and serine metabolism from the separate role of the MG-132 enantiomer as a low-activity proteasome-control compound.
HNRNPU Lactylation and (R)-MG132 Control
2026-11-12
A cervical-cancer study links HNRNPU K181 lactylation to PHGDH transcript regulation, serine metabolism, and tumor growth. (R)-MG132 is best interpreted as a proteasome-control material that can frame protein-turnover questions, not as the pharmacological basis of the reported metabolic mechanism.
What (R)-MG132 Can and Cannot Show
2026-11-11
A source-grounded interpretation of the HNRNPU K181 lactylation study, distinguishing its mechanistic evidence from the separate conceptual role of (R)-MG132 as a low-activity proteasome control.
When Context Changes a Cancer Result
2026-11-11
A cervical-cancer study illustrates how molecular, genetic, pharmacological, and model-specific contexts determine what a result can legitimately mean. It also clarifies why (R)-MG132, an MG-132 enantiomer used as a low-activity proteasome control, belongs to a different evidentiary question than the study’s central lactylation mechanism.
H-89 and Wnt-Driven Bone Metabolism
2026-11-10
The cited study places PKA-linked signaling within a broader Wnt–O-GlcNAcylation–glycolysis pathway that supports osteoblast differentiation and bone formation. H-89 is most informative as a pharmacological probe of the proposed early PKA–GFAT1 branch; the strongest causal evidence came from genetic manipulation and molecular analysis of PDK1 O-GlcNAcylation.
How HNRNPU Lactylation Rewires Cervical Cancer
2026-11-10
A literature-focused analysis of how HNRNPU K181 lactylation was linked to PHGDH expression, serine metabolism, and cervical cancer growth, with separate consideration of the proteasome-control role of (R)-MG132.
When Context Changes What a Result Means
2026-11-09
A cervical-cancer study illustrates why genetic, biochemical and pharmacological contexts give different meanings to similar growth readouts. The discussion also distinguishes the role of (R)-MG132 as a proteasome-control compound from evidence establishing the HNRNPU–PHGDH lactylation mechanism.